RenovoRx establishes RenovoCath Medical Advisory Board

RenovoRx (RNXT) announced the formation of a RenovoCath Medical Advisory Board, MAB, to support its clinical and strategic initiatives. “The formation of the MAB marks an exciting milestone for RenovoRx, and we’re honored to have such respected interventional radiology experts supporting advancement of the RenovoCath device,” said Ramtin Agah, MD, RenovoRx’s Chairman and Chief Medical Officer. “Their collective expertise will help guide real-world evidence generation as we advance our novel approach to localized, targeted drug delivery, aiming to improve outcomes for patients diagnosed with difficult-to-treat cancers.”